ISTO Technologies, Inc.
Scott Gill, CFO

ISTO is a privately-held regenerative medicine company developing novel products for the repair and regeneration of damaged or injured cartilage and bone.  We are developing unique orthobiologic products designed to provide off-the-shelf and cost effective long term regenerative treatment solutions for damaged cartilage through a proprietary allogeneic juvenile chondrocyte platform technology.  Our lead product candidates are RevaFlexTM, an engineered cartilage implant for articular knee cartilage repair and restoration, and NuQu®, a minimally invasive cell therapy designed to treat back pain and disability associated with chronic spinal disc degeneration, also known as discogenic back pain.  In addition to our pipeline of products in clinical development, ISTO manufactures and markets InQu®, a bone graft extender and substitute for spinal fusion applications that has been used in over 30,000 surgeries at U.S. hospitals to date.